ABIVAX Société Anonyme reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was EUR 2.3 million compared to EUR 2.3 million a year ago. Net loss was EUR 52 million compared to EUR 21.2 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.7 EUR | +1.28% | +1.93% | +29.33% |
May. 20 | BTIG Initiates Abivax at Buy Rating With $43 Price Target | MT |
May. 08 | Abivax: four abstracts to be presented on obefazimod | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.33% | 871M | |
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |
- Stock Market
- Equities
- ABVX Stock
- News Abivax
- ABIVAX Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2023